title: Enhanced pressor response to centrally administered vasopressin in WKY rats on high sodium diet.
abstract: Four week old Wistar-Kyoto (WKY) rats were divided into two groups. The experimental group (n = 7) was receiving a high sodium diet (3.28% Na) and the control group (n = 7) a normal sodium diet (0.22% Na). After 8 weeks, subjects were chronically implanted with the lateral cerebral ventricle (LCV) cannulas and with the femoral artery catheters. Three series of experiments were carried out on the experimental and control groups. In each series mean arterial pressure (MAP) and heart rate (HR) were recorded for 10 min before and 30 min after the LCV infusion. In series 1 artificial cerebrospinal fluid (aCSF) was administered (2 microl/15 s). In series 2 AVP was infused (20 ng/2 microl aCSF/15 s). In series 3 V1a receptor antagonist (V1 ANT), d(CH2)5[Tyr(Me)2,Ala-NH29]AVP, was applied (80 ng/microl aCSF/15 s). There was no difference in baseline MAP and HR between the experimental and control groups. LCV infusion of aCSF had no effect on MAP and HR. LCV infusion of AVP produced a significant increase of MAP, which was greater in the group on the high sodium diet than in the group on normal sodium diet. The experimental group showed a longer hypertensive effect of centrally applied AVP in comparison to the control. LCV administration of V1 ANT did not exert a significant effect on circulatory parameters. These results suggest that the prolonged high sodium diet does not induce hypertension in WKY rats, but it enhances the pressor function of the central vasopressinergic system.
authors.affiliation: Department of Experimental and Clinical Physiology, Medical University of Warsaw, 00-927 Warsaw, 26/28 Krakowskie Przedmieście St., Poland. tyzer@amwaw.edu.pl.
authors.forename: Tymoteusz
authors.initials: T
authors.lastname: Zera
authors.forename: Marcin
authors.initials: M
authors.lastname: Ufnal
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001127:Arginine Vasopressin / Q000031:analogs & derivatives* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D006339:Heart Rate / Q000187:drug effects; D009994:Osmolar Concentration; D011188:Potassium / Q000097:blood; D051381:Rats; D011921:Rats, Inbred WKY; D012964:Sodium / Q000097:blood; D012982:Sodium, Dietary / Q000494:pharmacology*; D013997:Time Factors; D014662:Vasoconstrictor Agents / Q000008:administration & dosage*; D014667:Vasopressins / Q000008:administration & dosage* / Q000037:antagonists & inhibitors
chemical_list: D012982:Sodium, Dietary; D014662:Vasoconstrictor Agents; D014667:Vasopressins; D001127:Arginine Vasopressin; C025043:vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-; D012964:Sodium; D011188:Potassium